Phimed Europe
1 known investors
Phi Med Europe develops NerveCheck, a portable medical device for early diagnosis and quantification of peripheral neuropathy, particularly diabetic neuropathy, using quantitative sensory testing (QST) technology. The device delivers rapid, non-invasive assessment of small and medium nerve fiber function for healthcare professionals in clinical settings.
Investors Β· 1
Frequently asked questions
- What does Phimed Europe do?
- Phi Med Europe develops NerveCheck, a portable medical device for early diagnosis and quantification of peripheral neuropathy, particularly diabetic neuropathy, using quantitative sensory testing (QST) technology. The device delivers rapid, non-invasive assessment of small and medium nerve fiber function for healthcare professionals in clinical settings.
- Who are Phimed Europe's investors?
- Phimed Europe's investors include Ship2B.